Login to Your Account

12-Month Data Expected Later This Year

Theravance Clipped by Mixed Relovair Data in 6-Month Trials

By Jennifer Boggs

Friday, June 3, 2011
Despite hailing two six-month pivotal studies' successes for Relovair in chronic obstructive pulmonary disease (COPD), South San Francisco-based Theravance Inc. saw its shares dinged by nearly a dollar Thursday as investors focused on the one endpoint that fell short of statistical significance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription